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Aims/hypothesis T helper type (Th) 17 cells have been shown to play important roles in mouse models 
of several autoimmune diseases that had been classified as Th1 diseases. In the NOD mouse, the 
relevance of Th1 and Th17 are controversial, because single cytokine-deficient NOD mice develop 
diabetes similarly to wild-type NOD mice. 
Methods We studied the impact of IL-17/IFN-γ receptor double deficiency in NOD mice on the 
development of insulitis/diabetes compared to the IL-17 single-deficient mice and wild-type mice.  
Results The IL-17 single-deficient NOD mice showed a delayed onset of diabetes and reduced severity 
of insulitis, but the cumulative incidence of long-life diabetes in the IL-17-deficient mice was similar 
to that in wild-type mice. The IL-17/IFN-γ receptor double-deficient NOD mice showed an apparent 
decline of longstanding diabetes onset, but not of insulitis compared to that in the IL-17 
single-deficient mice. We also found that double-deficient NOD mice had severe lymphopenic 
phenotype and preferential increase in Tregs among CD4+ T cells compared to the IL-17 
single-deficient mice and wild-type NOD mice.  Adoptive transfer study with CD4+CD25− T cells 
from young nondiabetic IL-17 single-deficient NOD mice, but not that from older mice, showed 
significantly delayed disease onset in immune-deficient hosts compared to that from the corresponding 
wild-type mice.  
Conclusions/interpretation These results indicate that IL-17/Th17 participates in the development of 
insulitis and that both IL-17 and IFN-γ signaling could synergistically contribute to the development 
of diabetes in NOD mice. 
 
Keywords IL-17, IFN-γ, NOD mice, type 1 diabetes, Th17, lymphopenia  
 
Abbreviations 
Th T helper type 
Scid severe combined immunodeficiency 
Tregs regulatory T cells 
 4 




Type 1 diabetes results from the autoimmune destruction of pancreatic β-cells mediated by CD4+ 
and CD8+ T cells [1]. T helper type (Th) 1 cells have been believed to play a key role in the 
pathogenesis of type 1 diabetes in the nonobese diabetic (NOD) mouse, because pancreatic 
islet-infiltrating mononuclear cells and diabetogenic T-cell clones derived from NOD islets show 
strong expression of T helper type (Th) 1 cytokines [2-5]. However, an unresolved issue remains as to 
why the elimination of Th1 cytokines or their signaling molecules, including IFN-γ, IL-12 and IFN-γ 
receptor does not to reduce the incidence of diabetes in NOD mice [6-10]. 
Th17 cells that produce IL-17 have been shown to play important roles in mouse models of several 
autoimmune diseases including experimental autoimmune encephalomyelitis, rheumatoid arthritis and 
autoimmune thyroiditis and others that had previously been thought to be Th1-dominant [11-16]. In 
the context of NOD mice, there are data suggesting that Th17 cells play a pathogenic role in type 1 
diabetes development [17]. The administration of GAD peptide inserted into immunoglobulin 
molecules inhibited diabetes development, dependent on the induction of splenic IFN-γ that inhibited 
IL-17 production [18], and treatment with neutralizing anti-IL-17 antibodies prevented the 
development of diabetes in NOD mice [19]. However, similarly to INF-γ knockout in NOD mice, an 
IL-17 knockdown NOD line created by directly introducing a short hairpin RNA construct does not 
alter diabetes susceptibility [20]. 
The differentiations of naïve CD4+ T cells to effector or regulatory T cells are more plastic than 
previously thought [21]. Th17 cells have been shown to convert to Th1 cells in a transfer model of 
colitis [22]. In type 1 diabetes, diabetogenic BDC2.5 CD4+ T cells polarized in vitro to the Th17 cell 
phenotype convert to Th1-like cells after adoptive transfer into NOD-Scid mice, ultimately causing 
β-cell destruction and diabetes[23, 24]. Thus, it is possible that the conversion of Th17 cells to Th1 
cells or Th1/Th17 cells co-expressing Th1 and Th17 cytokines in the pancreatic islets might counteract 
the disease inhibition by the elimination of a single cytokine gene from NOD mice. 
To address this issue we produced NOD mice genetically deficient in both IL-17 and IFN-γ 
receptor, and we evaluated the insulitis/diabetes development in comparison to IL-17 single-deficient 
 6 
NOD background mice. 
 
Materials and methods 
 
Mice 
NOD and NOD-Scid mice were purchased from Clea Japan (Tokyo Japan). IL-17-deficient NOD 
mice were generated as described (originally on a 129/Sv x C57BL/6 genetic background) [25]. IFN-γ 
receptor (IFN-γR)-deficient NOD mice were obtained from Dr. Osami Kanagawa (Laboratory for 
Autoimmune Regulation, RIKEN Research Center for Allergy and Immunology, Yokohama, Japan). 
All animal experiments described in this study were conducted with the approval of the institutional 
Animal Experimentation Committee, and were conducted in accordance with the Guidelines for 
Animal Experimentation of Nagasaki University.   
 
Establishment of IL-17 single-deficient and IL-17/IFN-γ receptor double-deficient NOD mice 
IL-17-deficient mice were backcrossed with NOD mice for eight successive generations. An 
analysis of the microsatellite markers of the diabetes susceptibility (Idd1-14) loci by PCR of the tail 
DNA as described [26] showed that the mice were homozygous for all of the NOD alleles (namely, 
IL-17-/- NOD mice). IFN-γ receptor (IFN-γR)-deficient NOD mice were crossed with IL-17-/- NOD 
mice, and the resulting F1, IL-17+/-/IFN-γR+/- NOD mice were intercrossed to produce IL-17 
single-deficient (IL-17-/-/IFN-γR+/+), IL-17/IFN-γ receptor double-deficient (IL-17-/-/IFN-γR-/-), and 
wild-type (wt) (IL-17+/+/IFN-γR+/+) NOD littermate mice. Only female mice were used for the present 
study. These mice were selected by PCR analysis of tail DNA as described[25, 26]. Tail DNA was 
extracted with the REDExtract-N-Amp Tissue PCR kit (Sigma, St. Louis, MO). 
 
Monitoring for spontaneous diabetes 
Blood glucose levels were monitored using the One-touch Ultra (Johnson & Johnson, Tokyo). 




Measurement of insulin autoantibodies 
Mice were bled at 8, 12 and 16 weeks of age, and serum samples were obtained and stored at 
−20°C until the antibody assay. The levels of insulin autoantibodies (IAAs) were evaluated by a 
96-well filtration plate micro-IAA assay, as described [27]. The index value of 0.01 was selected as the 
cutoff limit at the 100th percentile of 50 Balb/c and C57BL/6 mouse samples. 
 
Histology 
Pancreatic sections were histologically analysed by fixing the tissue specimens in 10% formalin 
and staining the paraffin-embedded samples with hematoxylin and eosin. A minimum of 30 islets from 
each mouse were examined microscopically by two different observers for the presence of insulitis. 
The severity of insulitis was scored as follows: 0, no lymphocytic infiltration; 1, lymphocytic 
infiltration occupying less than 25% of the total islet cell area; 2, lymphocytic infiltration occupying 
25%–50% of the total islet cell area; 3, lymphocytic infiltration occupying 50%–75% of the total islet 
cell area; 4, lymphocytic infiltration occupying more than 75% of the total islet cell area, or small 
retracted islets. 
 
Adoptive transfer experiments 
Donor CD4+CD25− T cells were purified from the spleens of 10- or 18-week-old prediabetic mice, 
and CD4+ T cells were purified from 15- to 22-week-old newly diabetic mice, using magnetic bead 
cell sorting (Miltenyi Biotech, Bergisch-Gladbach, Germany). Purified CD4+CD25− T cells or CD4+ T 
cells were adoptively transferred into 8- to 10-week old NOD-Scid mice, and the recipient mice were 
monitored for blood glucose biweekly after the adoptive transfer. 
 
Flow cytometric analysis 
Single cell suspensions of splenocytes (SPCs) were prepared from spleens of NOD mice at 10 
weeks of age. Red cells were lysed in ammonium chloride buffer.  For surface staining, cells were 
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stained for 20 min with the corresponding fluorescently labeled antibodies against surface molecules: 
CD3e (145-2C11), CD4 (GK1.5), CD8 (53-6.7), B220 (RA3-6B2), CD44 (IM7), CD62L (MEL-14) 
(all from eBioscience, San Diego, CA).  For the intracellular cytokine staining, the prepared SPCs 
were stimulated with 50 ng/ml phorbol 12-myristate 13-acetate (PMA) and 500 ng/ml ionomycin 
(both from Sigma) in the presence of 2 µM monensin for 5 h. Thereafter, the cells were stained with 
APC-Cy5 conjugated anti-CD4, followed by intracellular IFN-γ and IL-17 staining with 
PE-Cy7-conjugated anti-IL-17 (eBio17B7) and PerCP-Cy5.5-conjugated anti-INF-γ (XMG1.2) 
antibodies (all from eBioscience). Alternatively, the cells were resuspended with PBS and stained with 
FITC-conjugated anti-CD4 and PE-conjugated anti-CD25 (PC61) (BD Biosciences, San Diego, CA), 
followed by intracellular Foxp3 staining with PE-Cy5-conjugated anti-FoxP3 (FJK-16s; Foxp3 
staining kit, eBioscience). All cells were analysed on a FACSCanto II flow cytometry system using 
FACS Diva software (BD Biosciences). 
 
Statistics analysis 
Group differences were analysed by Mann-Whitney’s U test or Student’s t-test and differences 
between the Kaplan-Meier survival curves were estimated by the log-rank test using Dr. SPSS II 
software for Windows. The χ2 test was used to compare the incidence of diabetes at each week of age. 
P-values less than 0.05 were considered significant. The severity of the insulitis was analysed by a 
Ridit analysis, and t-levels higher than 1.96 or lower than −1.96 were considered significant. 
 
Results 
Diabetes and insulitis in the IL-17-deficient and IL-17/IFN-γ receptor-deficient NOD mice 
In our colony, ~75% of the female and 30%–40% of the male NOD mice usually develop diabetes 
by 48 weeks. A life-table analysis revealed that the onset of spontaneous diabetes in the 
IL-17-/-/IFN-γR+/+ NOD mice was significantly delayed compared to the onset in wt NOD littermate 
mice (p<0.05 by the log-rank test). The weekly incidence of diabetes in the IL-17-/-/IFN-γR+/+ NOD 
mice was also significantly lower from 15 to 24 weeks of age compared to that in wt NOD mice 
 9 
(p<0.05 by χ2 test). However, the cumulative incidence of diabetes at 50 weeks of age in the 
IL-17-/-/IFN-γR+/+ NOD mice was similar to that in the wt mice (IL-17-/-/IFN-γR+/+; 80.0 % vs. wt; 
85.7%) (Fig. 1a). As for the IL-17/IFN-γ receptor double-deficient NOD mice, the onset of diabetes 
was significantly suppressed compared to those in the IL-17-/-/IFN-γR+/+ NOD mice and in the wt 
NOD mice (IL-17-/-/IFN-γR-/- vs. IL-17-/-/IFN-γR+/+ and vs. wt, p=0.01 by the log-rank test). The 
weekly incidence of diabetes in the IL-17-/-/IFN-γR-/- NOD mice was significantly lower from 26 to 50 
weeks of age compared to that in the IL-17-/-/IFN-γR+/+ (p<0.05 by χ2 test) and from 16 until 50 weeks 
of age compared to that in wt NOD mice (p<0.05 by χ2 test). The cumulative incidence of diabetes at 
50 weeks of age in the IL-17-/-/IFN-γR-/- NOD mice was 43.8%, and disease suppression was 
maintained throughout the entire lifespan (Fig. 1a). 
We next compared the severity of the insulitis at 12 and 18 weeks of age in the IL-17-/-/IFN-γR-/-, 
IL-17-/-/IFN-γR+/+ and wt NOD mice. The severity of insulitis was significantly attenuated in the 
IL-17-/-/IFN-γR-/- and IL-17-/-/IFN-γR+/+ NOD mice compared to that in the wt mice (by Ridit analysis). 
However, there were no significant differences between the IL-17-/-/IFN-γR-/- and IL-17-/-/IFN-γR+/+ 
NOD mice at 12 or 18 weeks of age (Fig. 1b,c). 
 
IAAs levels in the IL-17 deficient and IL-17/IFN-γ receptor-deficient NOD mice 
We then determined the levels of IAAs in the IL-17-/-/IFN-γR-/-, IL-17-/-/IFN-γR+/+ and wt NOD 
mice at 8, 12, and 16 week of ages. Despite the suppression of insulitis/diabetes development in the 
IL-17-/-/IFN-γR-/- and IL-17-/-/IFN-γR+/+ mice, the serum levels of IAAs and the percentage of mice 
positive for IAAs did not significantly differ between the IL-17-/-/IFN-γR-/- and wt NOD mice or 
between the IL-17-/-/IFN-γR+/+ and wt mice, at all ages (data not shown). 
 
Adoptive transfer of the effector CD4+ T cells from IL-17-/- NOD mice into NOD-Scid mice 
Our aforementioned data suggest that IL-17 may play an important role in the development of 
insulitis. However, it is possible that IL-17 is associated with diabetes development only in younger 
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NOD mice and not in elder mice, since disease inhibition by IL-17 single-deficiency was not 
maintained past 24 weeks of age. We therefore compared the diabetogenicity of CD4+ effector T cells 
from IL-17-/- NOD and wt NOD mice at different ages to adoptively transfer diabetes into NOD-SCID 
mice. 
The adoptive transfer of purified CD4+CD25− effector T cells from 10-week-old nondiabetic 
IL-17-/- mice demonstrated significantly delayed disease onset compared to those from the 
corresponding wt NOD mice (Fig. 2a). No significant differences in disease development between 
IL-17-/- and wt NOD mice were observed following adoptive transfer with CD4+CD25− T cells from 
18-week-old nondiabetic mice (Fig. 2b), or with CD4+ T cells from 15- to 22-week-old newly diabetic 
mice (Fig. 2c).  
 
Flow cytometric analysis for CD4+ T cells in the IL-17 deficient and IL-17/IFN-γ 
receptor-deficient NOD mice 
We firstly counted lymphocyte numbers and found that 10-week-old IL-17-/-/IFN-γR-/- NOD mice 
had significantly reduced numbers of lymphocytes including CD3+, CD4+ and CD8+ T cells and B 
cells in the spleen and the numbers were almost half or less than half of those in the IL-17-/-/IFN-γR+/+ 
or wt NOD mice. The percentages of CD4+ T cells, CD8+ T cells, and B cells in the SPCs were not 
significantly different among three groups (Table 1). As for the CD4+ T cell fraction, the production of 
cytokines was evaluated by intracellular cytokine staining after stimulation with PMA and ionomycin 
for 5 h. The percentages of IFN-γ-producing cells did not significantly differ among the three groups, 
although the number in the IL-17-/-/IFN-γR-/- mice tended to be decreased compared to the other 
groups (3.22 ± 1.37 % vs. 4.42 ± 0.90 % in IL-17-/-/IFN-γR+/+ mice, p=0.11 vs. 4.19 ± 0.66 % in wt 
mice, p=0.11, respectively) (Fig. 3a-c,d). IL-17-producing cells among the CD4+ T cells were 
observed only in wt mice (0.34 ± 0.11 %) as expected, and double-positive cells with IL-17 and IFN-γ 
were not observed in any of the groups (Fig. 3a-c,e). 
We next determined the activation markers including CD44 and CD62L on CD4+ T cells and 
regulatory T cells (Tregs) population without stimulation.  No significantly differences were found in 
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level of activation markers on the CD4+ T cells among three groups (Fig. 4 a-c,g).  As for Tregs, the 
percentage of Foxp3+ CD25+ cells to CD4+ T cells was significantly higher in the IL-17-/-/IFN-γR-/- 
mice than in the IL-17-/-/IFN-γR+/+ mice (6.8 ± 0.96% vs. 4.7 ± 0.54%, p<0.01) and in the wt mice (vs. 
5.4 ± 0.32%, p<0.05) (Fig. 4 d-f,h). The preferential increase of Tregs could be systemic phenotype 
since higher percentage of CD25+ cells to CD4+ T cells were observed in mesenteric lymph nodes or 
pancreatic draining lymph nodes (data not shown).   
 
Discussion 
In the present study, we first determined the impact of the genetic deletion of IL-17, a potent 
proinflammatory cytokine, in the NOD mouse to investigate whether IL-17 is involved in the 
pathogenesis of type 1 diabetes. Our results showed that the severity of insulitis was attenuated in both 
the IL-17 single-deficient and IL-17/IFN-γR double-deficient NOD mice, with no significant 
difference between these two types of mice, indicating that IL-17 rather than IFN-γ signaling plays a 
key role in the build-up of the inflammatory infiltrate into islets in NOD mice, as is the case for 
numerous other autoimmune diseases (Fig. 1b,c)[11-16]. This result is also consistent with that 
obtained by Martin-Orozco et al. describing that in vitro-polarized Th17 cells derived from BDC2.5 
TCR-Tg NOD mice transfer extensive insulitis, but does not produce diabetes into newborn NOD 
mice [23]. 
Regarding the development of diabetes, we found that the onset of diabetes was significantly 
delayed in the IL-17 single-deficient NOD mice, although they remained susceptible to long-life 
diabetes, as is consistent with the report by Joseph et al. [20] (Fig. 1a). In the different line of IL-17 
single-deficient NOD mice (original IL-17-/- NOD mice) (n=47) and the wt littermate control mice 
(n=44), we observed the same delayed-onset result in IL-17-/- NOD mice (vs. Control, p<0.05 by the 
log-rank test) (Suppl. Fig. 1). 
Previous studies have demonstrated that the phenotype of delayed onset in IFN-γR-deficient NOD 
mice is due to the presence of 129-derived genes closely linked to the knockout gene rather than due to 
a lack of the target gene [10, 28]. However, our mapping study with polymorphic markers on 
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chromosome 1 distinguishing NOD from the 129 alleles showed that the maximum interval of the 
129-derived genes surrounding the IL-17a gene was less than 1 cM (Suppl. Fig. 2), and there are no 
identified iddm loci in this region, suggesting that the resistance to the development of insulitis and 
diabetes in the IL-17-/- NOD mice is attributable to the lack of IL-17 rather than to the influence of the 
129-derived genes. 
The phenotype of delayed onset in the IL-17 single-deficient NOD mice indicates that IL-17 might 
participate in the pathogenesis of the early phase of the development of diabetes. This hypothesis was 
verified by our adoptive transfer study, which showed the successful adoptive transfer of diabetes by 
CD4+CD25− effector T cells from younger nondiabetic wt mice but not by those from the IL-17 
single-deficient NOD mice of the same age (Fig. 2a). However, such attenuation of diabetes 
development by IL-17-deficient diabetogenic T cells was no longer seen following a similar transfer of 
the same cells derived from older nondiabetic or diabetic mice (Fig. 2b,c). Taken together, the present 
results suggest that IL-17 participates in the pathogenesis of the early phase of the development of 
diabetes, but elimination of IL-17 could be readily dispensable in the late phase of diabetes. 
In vitro-polarized Th17 cells derived from BDC2.5 TCR-Tg NOD mice do not transfer diabetes in 
newborn NOD mice but do transfer diabetes in immune-deficient hosts through conversion to Th1 
cells or Th1/Th17 cells co-expressing Th1 and Th17 cytokines[23, 24].  We hypothesized that such a 
conversion of Th17 to Th1 cells or to Th1/Th17 cells may have compensated for the disease inhibition 
by IL-17 single deficiency in NOD mice in the present study. To test our hypothesis, we also evaluated 
the impact of the genetic deletion of both IL-17 and IFN-γ signaling in the NOD mice to determine 
whether such a double deficiency could clearly suppress disease. As hypothesised, IL-17/IFN-γR 
double deficiency significantly suppressed the longstanding incidence of diabetes compared to IL-17 
single deficiency in NOD mice (Fig. 1a). These results indicated that Th1 and Th17 cytokines could 
synergistically contribute to the development of diabetes in NOD mice, since IFN-γR-deficient NOD 
mice exhibit minimal or no inhibition of disease[10, 28].  
We fortuitously found that IL-17/IFN-γR double-deficient NOD mice had severe lymphopenic 
phenotype. Previous study demonstrated that wild-type NOD mice have mild lymphopenia compared 
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to nonautoimmune strain and as a result compensatory homeostatic expansion of T cells generate 
anti-islet autoimmunity resulting in the development of diabetes[29]. In contrast, NOD mice harboring 
C57BL/6-derived Idd3 genetic interval (which encodes the IL-2 and IL-21 genes) (NOD.Idd3 mice) 
are disease–resistance, are not lymphopenic. Recently it has been shown that naïve T cells from NOD 
mice exhibit a greater propensity to differentiate in to Th17 cells than those from NOD.Idd3 mice and 
IL-21 signaling in antigen presenting cells plays a central role in such Th17 cell development[30].   
Alternatively, several studies have demonstrated that diabetes susceptibility and protection in NOD 
mice are correlated with lymphopenia and homeostatic expansion under a variety of experimental 
conditions. Thymectomy at weaning or treatment with cyclophosphamide which causes lymphocyte 
apoptosis accelerate diabetes onset in NOD mice [31, 32].  In contrast, immunization with complete 
Freund’s adjuvnt (CFA) increased T cell numbers and protects NOD mice from diabetes [29, 33].  
Kanagawa et al have reported that IFN-γR deficiency abrogates to cyclophosphamide-induced 
acceleration of diabetes and CFA mediated protection in NOD mice[34, 35].  Thus, Th17 cell 
development and IFN-γ signaling might play a critical role of diabetes susceptibility mediated by 
lymphopenia-induced homeostatic expansion in NOD mice, although the precise kinetics and 
mechanisms of severe lymphopenia in these mice are still being elucidated.   
We also found that double-deficienct NOD mice had preferential increase in Tregs among CD4+ 
splenic T cells.  Several recent findings highlight the plasticity within the CD4+ Th cell population 
including Th1, Th2, Th17 and Tregs, and Th17 cells and Tregs are more plastic than Th1/Th2 cells 
[21].  Networks of cytokines are critical for determining CD4+ T cell fates and effector cytokines [36]. 
For example, Thomas et al clearly demonstrated that systemic overproduction of IL-1β in 6- to 
16-week-old NOD mice impairs Treg function and promotes the Treg to Th17 conversion [37]. A pair 
of studies showed that ex vivo or in vitro-generated Th17 cells can be converted to Th1 phenotype by 
combined IFN-γ and IL-12 signaling through epigenetic processes [38, 39]. As described above, in 
vitro-polarized Th17 cells are readily reprogrammed into other T cell lineages upon transfer into 
lymphopenic hosts [23, 40]. Of note, the treatment with cyclophosphamide not only fails to accelerate 
diabetes but also confer permanent protection of diabetes by the preferential generation of Tregs in the 
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IFN-γR deficient NOD mice [34].  It is possible that IFN-γR deficiency under the lymphopenic 
condition inhibits such a Th shift from Th1 to Th17 or from Tregs to another effector T-cell lineage, 
resulting in a preferential increase in Tregs population and disease-resistance and in our 
double-deficient NOD mice. 
Thus, we here demonstrated that that IL-17/Th17 participates in the development of insulitis and 
that both IL-17 and IFN-γ signaling could synergistically contribute to the effector T cells/Tregs 
balance to effector T cells during homeostasis expansion and subsequent development of diabetes in 
NOD mice.  
From the clinical point of view, the therapeutic efficacy of the inhibition of Th17 cells in some 
autoimmune diseases has been demonstrated [18, 19]. It was reported that children with new-onset 
type 1 diabetes have an increased proportion of memory CD4+ cells which have increased IL-17 
secretion, suggesting that upregulation of Th17 immunity is associated with human type 1 diabetes[41, 
42]. This implies a novel potential therapeutic strategy for human type 1 diabetes based on the control 
of IL-17 immunity. However, the results presented in the present study indicate that a single blockade 
of an effector cytokine such as IL-17 or IFN-γ readily compensates for the Th shift from Tregs to 
effector Th lineage through the multiple networks of cytokines. The appropriate timing or therapeutic 
strategy to inhibit the Treg/Teff conversion — such as a combination blockade of multiple cytokines or 
transcriptional factors such as JAK-STAT pathway, Runx3, and IRF-4 — should be carefully 
considered with the goal of preventing or delaying the development of type 1 diabetes [36].
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Fig 1 Diabetes and insulitis in the IL-17 deficient and IL-17/IFN-γ receptor deficient NOD mice. (a) 
Incidence of diabetes in wt NOD mice (■, n=21), IL-17-/-/IFN-γR+/+ NOD mice (○, n=20) and 
IL-17-/-/IFN-γR-/- NOD mice (▲, n=16). The χ2 test was used to compare the incidence of diabetes at 
each week of age (*: p<0.05, IL-17-/-/IFN-γR+/+ vs. wt, †: p<0.05 IL-17-/-/IFN-γR-/- vs. wt, ‡: p<0.05, 
IL-17-/-/IFN-γR+/+ vs. IL-17-/-/IFN-γR-/-). The severity of insulitis in 12- (b) or 18-week-old (c) wt NOD 
mice (n=5), IL-17-/-/IFN-γR+/+ NOD mice (n=5) and IL-17-/-/IFN-γR-/- NOD mice (n=5). The severity 
of insulitis was scored as described in materials and methods. Levels of insulitis: 0; white bar fill, 1; 
dotted fill, 2; horizontal-stripes fill, 3; diagonal-stripes fill and 4; black bar fill. A T Ridit analysis was 
used, and T-levels of higher than 1.96 or lower than −1.96 were considered significant.   
 
Fig 2 Adoptive transfer of effector CD4+ T cells into 8- to 10-week-old NOD-SCID mice. (a) 
CD4+CD25− T cells (1 x 107) from 10-week-old nondiabetic IL-17-/- NOD mice (○, n= 5) or wt NOD 
mice (■, n= 9) were transferred into recipient NOD-SCID mice. *p=0.03 by the log-rank test. (b) 
CD4+CD25− T cells (1 x 107) from 18-week-old nondiabetic IL-17-/- NOD mice (○, n= 10) or wt NOD 
mice (■, n= 6) were transferred into recipient NOD-SCID mice. p=0.84 by the log-rank test. (c) CD4+ 
cells (5.5 x 106) from 15-to 22-week old freshly diabetic IL-17-/- NOD mice (○, n=10) or wt NOD 
mice (■, n=10) were transferred into recipient NOD-SCID mice. p=0.48 by the log-rank test. 
 
Fig. 3 IFN-γ+/IL-17+ cells in CD4+ splenocyte T cells in the IL-17 deficient and IL-17/IFN-γ 
receptor-deficient NOD mice. Splenocytes were prepared, stimulated with PMA and ionomycin for 5 h, 
stained for cell surface CD4 and intracellular IFN-γ and IL-17, and analysed with flow cytometry (a-c). 
Representative staining of CD4+ splenocytes for intracellular IFN-γ and/or IL-17. (d,e), Numeration of 
Th1 and Th17 cells, respectively. The data are means ± S.D. (n=5). 
 
Fig. 4 Activation markers and Foxp3+CD25+ cells in CD4+ splenocyte T cells. Unstimulated SPCs 
 23 
were stained for cell-surface CD4, CD62L, CD44 and CD25 and intracellular Foxp3 and analysed 
with flow cytometry. Representative staining of CD4+ SPCs for (a-c) CD62L and CD44 and (d-f) 
CD25 and Foxp3. Numeration of (g) each CD44lowCD62Lhi, CD44hiCD62Lhi, CD44hiCD62Llow cells in 
wt NOD mice (black bar fill;), IL-17-/-/IFN-γR+/+ NOD mice (solid grey fill) and IL-17-/-/IFN-γR-/- 
NOD mice (white bar fill) and (h) CD25+Foxp3+ cells. The data are means ± S.D. (n =5), and group 
differences were analysed by Mann-Whitney U test. *p<0.05, ***p<0.001 
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The results are shown as means ± S.D. (*, P<0.001 **, P<0.005 versus wt or IL-17-/-/IFN-γR+/+).  
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